### Table 1: Antitumor activity in the CLAP study and in the current analysis

<table>
<thead>
<tr>
<th>Antitumor Activity</th>
<th>CLAP study population (N = 45)</th>
<th>Subpopulation in the current analysis (N = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR</td>
<td>25 (55.6)</td>
<td>21 (65.6)</td>
</tr>
<tr>
<td>DCR</td>
<td>37 (82.2)</td>
<td>30 (93.8)</td>
</tr>
<tr>
<td>Best overall response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>2 (4.4)</td>
<td>2 (6.3)</td>
</tr>
<tr>
<td>PR</td>
<td>23 (51.1)</td>
<td>19 (59.4)</td>
</tr>
<tr>
<td>SD</td>
<td>12 (26.7)</td>
<td>9 (28.1)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>4 (8.9)</td>
<td>2 (6.3)</td>
</tr>
<tr>
<td>Not available</td>
<td>4 (8.9)</td>
<td>–</td>
</tr>
</tbody>
</table>

Data are presented as No. (%), unless otherwise specified.

ORR, objective response rate; DCR, disease control rate; CR, complete response; PR, partial response; SD, stable disease.